(Reuters) - Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on ...

Softgel Capsules Market. The global softgel capsules market is on track to achieve a valuation of USD 1.1 billion by the end ...

The firms entered into a merger agreement in February for Novo Holdings to acquire Catalent in an all-cash transaction worth $16.5 billion. That deal still expects to close toward the end of ...

Earnings Estimate Revisions for Catalent For the fiscal year ending June 2025, this maker of drug delivery technologies is expected to earn $1.36 per share, which is a change of 444% from the year ...

Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to contract manufacturer Ardena. Financial details of the agreement ...

A Catalent spokesperson reiterated the company's position on the deal in a statement on Friday to Reuters in response to the letter: "Novo Holdings’ pending acquisition of Catalent will further ...

Want a mattress that will give you a cool and comfortable sleep experience? Here are our top picks of the best gel mattresses, tested by CNET's team of sleep experts. McKenzie, a Certified Sleep ...

Baird analyst Eric Coldwell downgraded the rating on Catalent (CTLT – Research Report ... and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops ...

Want a manicure that may last up to a month and can be removed in around 15 minutes? Enter soft gel nail extensions. At Vanity Projects, a Lower East Side salon, these nails with this design cost ...

Below, they break down the pros and cons of each. There are several types of gel nails, but soft gel and hard gel are the ...

1 Day CTLT -0.63% DJIA 0.79% S&P 500 0.47% Health Care/Life Sciences -0.97% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...